Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients

Clinical Transplantation

Volumn 25, Issue 2, 2011, Pages

  Ing, Steven W ^a   Sinnott, Loraine T ^b   Donepudi, Sirisha ^a   Davies, Elizabeth A ^a   Pelletier, Ronald P ^a   Lane, Nancy E ^c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone mineral density; Dual energy X ray absorptiometry; Glucocorticoid withdrawal; Kidney transplant; Renal transplant; Steroid withdrawal

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CREATININE; CYCLOSPORIN; ESTROGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PREDNISONE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE TURNOVER; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; GRAFT RECIPIENT; HIP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BONE DENSITY; CYCLOSPORINE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES;

EID: 79953323642     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01344.x     Document Type: Article

References (64)

1. Canalis E. Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996: 81: 3441.
2. Kream BE, Lukert BP. Clinical and basic aspects of glucocorticoid action on bone. In: Bilezikian JP, Raisz LG, Rodan GA eds. Principles of Bone Biology, Vol. 1. San Diego: Academic Press, 2002: 723.
3. Sambrook P, Birmingham J, Kempler S et al. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990: 5: 1211.
4. Chappard D, Legrand E, Basle MF et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 1996: 11: 676.
5. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000: 15: 993.
6. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 2000: 160: 2917.
7. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991: 46: 803.
8. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995: 54: 801.
9. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003: 48: 3224.
10. Kumagai S, Kawano S, Atsumi T et al. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol 2005: 32: 863.
11. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998: 102: 274.
12. Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004: 34: 593.
13. Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS. Osteocyte viability with glucocorticoid treatment: relation to histomorphometry. Ann Rheum Dis 2003: 62: 1215.
14. Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999: 140: 4382.
15. Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A, Nordin BE. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 1990: 46: 305.
16. Sambrook PN, Eisman JA, Champion GD, Pocock NA. Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 1988: 31: 973.
17. Reid IR, Ibbertson HK, France JT, Pybus J. Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. Br Med J (Clin Res Ed) 1985: 291: 574.
18. Reid IR, Ibbertson HK. Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm Res 1987: 27: 200.
19. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994: 9: 1097.
20. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006: 79: 129.
21. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000: 58: 396.
22. Abbott KC, Oglesby RJ, Hypolite IO et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol 2001: 11: 450.
23. Vautour LM, Melton LJ III, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT. Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 2004: 15: 160.
24. Ball AM, Gillen DL, Sherrard D et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002: 288: 3014.
25. Stehman-Breen CO, Sherrard DJ, Alem AM et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000: 58: 2200.
26. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999: 67: 1218.
27. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002: 13: 551.
28. Heaf JG. Bone disease after renal transplantation. Transplantation 2003: 75: 315.
29. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res 2004: 19: 1919.
30. Cunningham J. Posttransplantation bone disease. Transplantation 2005: 79: 629.
31. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005: 90: 2456.
32. Hamdy NA. Calcium and bone metabolism pre- and post-kidney transplantation. Endocrinol Metab Clin North Am 2007: 36: 923.
33. Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am 2007: 36: 937.
34. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991: 325: 544.
35. Kwan JT, Almond MK, Evans K, Cunningham J. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab 1992: 18: 166.
36. Epstein S, Inzerillo AM, Caminis J, Zaidi M. Disorders associated with acute rapid and severe bone loss. J Bone Miner Res 2003: 18: 2083.
37. Almond MK, Kwan JT, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12months following renal transplantation. Nephron 1994: 66: 52.
38. Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20years after transplantation. Transplantation 1995: 59: 982.
39. Grotz WH, Mundinger FA, Rasenack J et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995: 10: 2096.
40. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996: 28: 105.
41. Ferguson RM, Henry ML, Elkhammas EA et al. Twenty years of renal transplantation at The Ohio State University: the results of five eras of immunosuppression. Am J Surg 2003: 186: 306.
42. Farmer CK, Hampson G, Abbs IC et al. Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant 2006: 6: 2929.
43. Pelletier RP, Akin B, Ferguson RM. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant 2006: 20: 10.
44. Vokes TJ. Blood calcium, phosphate, and magnesium. In: Favus MJ ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: American Society for Bone and Mineral Research, 2006: 123.
45. Stevens L. PRD. Calculation of the creatinine clearance. UpToDate, 2008.
46. Hui SL, Gao S, Zhou XH et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res 1997: 12: 1463.
47. Lu Y, Fuerst T, Hui S, Genant HK. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int 2001: 12: 438.
48. Farmer CK, Hampson G, Vaja S et al. Late low dose steroid withdrawal in renal transplant recipients increase bone formation and bone mineral density without altering renal function: a randomized controlled trial. J Bone Miner Res 2002: 17(S1): S158.
49. Gomez B Jr, Ardakani S, Ju J et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995: 41: 1560.
50. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993: 77: 1046.
51. Roe SD, Porter CJ, Godber IM, Hosking DJ, Cassidy MJ. Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism. Osteoporos Int 2005: 16: 142.
52. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006: 69: 1945.
53. Moe S, Drueke T, Cunningham J et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009: 113: S1.
54. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995: 333: 1437.
55. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996: 348: 1535.
56. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998: 280: 2077.
57. Heaney RP, Zizic TM, Fogelman I et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002: 13: 501.
58. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999: 282: 1344.
59. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999: 68: 1865.
60. Pascual J, Quereda C, Zamora J, Hernandez D. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004: 78: 1548.
61. Pascual J, Quereda C, Zamora J, Hernandez D. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc 2005: 37: 3746.
62. Opelz G, Dohler B, Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005: 5(4 Pt 1): 720.
63. Sivaraman P, Nussbaumer G, Landsberg D. Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am J Kidney Dis 2001: 37: 1162.
64. Laftavi MR, Stephan R, Stefanick B et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005: 137: 364.